{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:08:10Z","timestamp":1787846890588,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab\/lenalidomide\/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide\/dexamethasone (Rd) in relapsed\/refractory multiple myeloma (RRMM) patients. We report an updated subgroup analysis of POLLUX based on cytogenetic risk. The cytogenetic risk was determined using fluorescence in situ hybridization\/karyotyping; patients with high cytogenetic risk had <jats:italic>t<\/jats:italic>(4;14), <jats:italic>t<\/jats:italic>(14;16), or del17p abnormalities. Minimal residual disease (MRD; 10<jats:sup>\u20135<\/jats:sup>) was assessed via the clonoSEQ<jats:sup>\u00ae<\/jats:sup> assay V2.0. 569 patients were randomized (D-Rd, <jats:italic>n<\/jats:italic>\u2009=\u2009286; Rd, <jats:italic>n<\/jats:italic>\u2009=\u2009283); 35 (12%) patients per group had high cytogenetic risk. After a median follow-up of 44.3 months, D-Rd prolonged progression-free survival (PFS) versus Rd in standard cytogenetic risk (median: not estimable vs 18.6 months; hazard ratio [HR], 0.43; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and high cytogenetic risk (median: 26.8 vs 8.3 months; HR, 0.34; <jats:italic>P<\/jats:italic>\u2009=\u20090.0035) patients. Responses with D-Rd were deep, including higher MRD negativity and sustained MRD-negativity rates versus Rd, regardless of cytogenetic risk. PFS on subsequent line of therapy was improved with D-Rd versus Rd in both cytogenetic risk subgroups. The safety profile of D-Rd by cytogenetic risk was consistent with the overall population. These findings demonstrate the improved efficacy of daratumumab plus standard of care versus standard of care in RRMM, regardless of cytogenetic risk.<\/jats:p>","DOI":"10.1038\/s41408-020-00375-2","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T11:03:11Z","timestamp":1604487791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Daratumumab, lenalidomide, and dexamethasone in relapsed\/refractory myeloma: a cytogenetic subgroup analysis of POLLUX"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6429","authenticated-orcid":false,"given":"Jonathan L.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Leiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Joy Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takezako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-394X","authenticated-orcid":false,"given":"Hila","family":"Magen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miles Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tineke","family":"Casneuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Krevvata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Ukropec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"375_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840\u20131848 (2011).","journal-title":"J. Immunol."},{"key":"375_CR2","doi-asserted-by":"crossref","unstructured":"Lammerts van Bueren, J. et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 124, abstract 3474 (2014).","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"375_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311\u2013321 (2015).","journal-title":"MAbs"},{"key":"375_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk, M. B. et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor\u2013mediated cross-linking. J. Immunol. 197, 807\u2013813 (2016).","journal-title":"J. Immunol."},{"key":"375_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik, J. et al. Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384\u2013394 (2016).","journal-title":"Blood"},{"key":"375_CR6","doi-asserted-by":"crossref","unstructured":"Chiu, C. et al. Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLLUX). Blood 128, abstract 4531 (2016).","DOI":"10.1182\/blood.V128.22.4531.4531"},{"key":"375_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams 3rd","year":"2019","unstructured":"Adams, H. C. 3rd et al. High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A 95, 279\u2013289 (2019).","journal-title":"Cytometry A"},{"key":"375_CR8","unstructured":"DARZALEX\u00ae (daratumumab) injection, for intravenous use [package insert]. (Janssen Biotech, Inc., Horsham, PA, 2019)."},{"key":"375_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"375_CR10","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","volume":"34","author":"NJ Bahlis","year":"2020","unstructured":"Bahlis, N. J. et al. Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34, 1875\u20131884 (2020).","journal-title":"Leukemia"},{"key":"375_CR11","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"375_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan, A. M. & Rajkumar, S. V. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 5, e365 (2015).","journal-title":"Blood Cancer J."},{"key":"375_CR13","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/leu.2009.174","volume":"23","author":"R Fonseca","year":"2009","unstructured":"Fonseca, R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210\u20132221 (2009).","journal-title":"Leukemia"},{"key":"375_CR14","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 103, 2088\u20132096 (2018).","journal-title":"Haematologica"},{"key":"375_CR15","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau, H. et al. Evaluation of sustained minimal residual disease (MRD) negativity in relapsed\/refractory multiple myeloma (RRMM) patients (pts) treated with daratumumab in combination with lenalidomide plus dexamethasone (D-Rd) or bortezomib plus dexamethasone (D-Vd): analysis of Pollux and Castor. Poster presented at: 60th Annual Meeting of the American Society of Hematology; 1\u20134 December 2018; San Diego, CA: Abstract 3272 (2018).","DOI":"10.1182\/blood-2018-99-113177"},{"key":"375_CR16","unstructured":"Chiu, C. et al. Next generation sequencing (NGS) methodology for determining cytogenetic risk status in the daratumumab phase 3 CASTOR and POLLUX studies in relapsed or refractory multiple myeloma (RRMM). Presented at: 22nd Congress of the European Hematology Association; 22\u201325 June 2017; Madrid, Spain: Abstract S100 (2017)."},{"key":"375_CR17","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau, H. et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128, 1174\u20131180 (2016).","journal-title":"Blood"},{"key":"375_CR18","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1002\/cncr.31680","volume":"124","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 124, 4032\u20134043 (2018).","journal-title":"Cancer"},{"key":"375_CR19","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau, H. et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood 130, 2610\u20132618 (2017).","journal-title":"Blood"},{"key":"375_CR20","unstructured":"Weisel, K. et al. Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: updated subgroup analysis of CASTOR. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; 31 May\u20134 June 2019; Chicago, IL (2019)."},{"key":"375_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","volume":"20","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin. Lymphoma Myeloma Leuk. 20, 509\u2013518 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00375-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00375-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:36:31Z","timestamp":1670250991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-00375-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-00375-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"18 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L.K. consulted for Celgene, Takeda, Amgen, Bristol-Myers Squibb, Janssen, Sanofi Genzyme, and Tecnopharma; received honoraria from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi Genzyme, Takeda, and Tecnopharma; and held membership on a board of directors or advisory committee for Pharmacyclics, Incyte, TG Therapeutics, and Karyopharm. M.A.D. received honoraria from Amgen, Takeda, Celgene, Janssen, and Bristol-Myers Squibb. D.W. received honoraria from and served on advisory committees for Amgen, Antengene, Celgene, Janssen, Karyopharm, Sanofi, and Takeda. L.B. received honoraria from Celgene, Amgen, Takeda, and Janssen; served in a consulting or advisory role for Amgen, Celgene, Takeda, and Janssen; and had travel, accommodations, or other expenses paid or reimbursed by Celgene, Takeda, Janssen, Amgen, and Novartis. G.C. received honoraria from Amgen, Bristol-Myers Squibb, GlycoMimetics, Seattle Genetics, Celgene, Janssen, Takeda, and Sanofi; and received research funding from Celgene, Janssen, and Takeda. P.J.H. received investigator meeting support from Celgene, Janssen, La Jolla, and Novartis. P.M. received honoraria from and served in a consulting or advisory role for Janssen, Celgene, Amgen, and AbbVie. H.J.S. received honoraria from and served in a consulting or advisory role for Celgene, Janssen, and Amgen; and received research funding from Janssen, GlaxoSmithKline, and Karyopharm. S.I. received honoraria from Janssen, Celgene, Ono, Takeda, Bristol-Myers Squibb, Novartis, and Daiichi Sankyo; and received research funding from Janssen, Chugai, Kyowa Hakko Kirin, Ono, Takeda, Celgene, Novartis, Daiichi Sankyo, Sanofi, AbbVie, Gilead, and Bristol-Myers Squibb. H.M.P. received honoraria from Janssen and Celgene; and received research funding from Amgen and Takeda. T. Cochrane received travel expenses from Bristol-Myers Squibb, Novartis, Celgene, and Takeda. A.O. served in a consulting or advisory role for Celgene, Amgen, Janssen, and Takeda; and served on a speakers bureau for Amgen and Celgene. N.J.B. received honoraria from Celgene, Janssen, AbbVie, Sanofi, Takeda, and Amgen; served in a consulting or advisory role for Celgene, Janssen, Amgen, Sanofi, Takeda, and AbbVie; received research funding from Celgene; and had travel, accommodations, or other expenses paid or reimbursed by Celgene and Janssen. A.C. served in a consulting or advisory role for Janssen, Celgene, Novartis Pharmaceuticals, Amgen, Bristol-Myers Squibb, Karyopharm, Sanofi, Seattle Genetics, Oncopeptides, Millennium\/Takeda, and Antengene; and received research funding from Janssen, Millennium\/Takeda, Celgene, Amgen, Pharmacyclics, and Seattle Genetics. L.O. and T. Casneuf are employees of Janssen and hold Johnson & Johnson stock options. S.T., M.K., J.U., and R.K. are employees of Janssen. S.Z.U. served in a consulting or advisory role for Sanofi, Takeda, Celgene, Skyline, Amgen, AbbVie, Mundipharma, Seattle Genetics, and Janssen; and received grants from Sanofi, Takeda, Celgene, Skyline, Amgen, AbbVie, Mundipharma, Seattle Genetics, Janssen, Bristol-Myers Squibb, and Pharmacyclics. J.S.-M. served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp & Dohme, Novartis, Takeda, Sanofi, Roche, AbbVie, GlaxoSmithKline, and Karyopharm. M.L., J.M., K.K., N.T., H.M., J.S.K., and H.A.-L. declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"111"}}